Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.

SandozNorvatisDiv_1200

Sandoz Inc.'s application package for its biosimilar to Amgen Inc.'s Enbrel continues to signal to FDA that the company is ready to move forward on interchangeability even if the agency is not.

A clinical study with multiple switches between GP2015 and its reference product was part of Sandoz's application to determine it...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics